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Herpes Zoster (HZ) and its main complication, post-herpetic neu-
ralgia (PHN), represent an important public health issue because 
of their relevant burden within older adult population and the 
actual suboptimal therapeutic management of the diseases.
Incidences of HZ and PHN are comparable all over the world 
and are closely related with the population age. Epidemiological 
data collected in Italy about HZ and its complications confirmed 
the trend registered in North America and Europe. Moreover HZ 
related burden is exacerbated by a significant economic impact 
related to both direct and indirect costs.
Since 2006 a live, attenuated varicella zoster virus vaccine, that 
contains VZV Oka strain [Zostavax, Merck & Co., Inc.], was 
licensed for the prevention of HZ and PHN in adults aged ≥ 60 
years. Since 2011, the licensure has been extended to adults 
between 50 and 59 years. The vaccine has demonstrated a good 
immunogenicity, efficacy and safety profiles in two pivotal phase 
III clinical trials and the effectiveness was further confirmed after 
vaccine licensure. Pharmaco-economic studies concluded that 
HZ vaccine is cost-effective in most European countries and gen-
erally supported the economic value of this vaccination.
The vaccine is actually recommended in USA, Canada and sev-
eral European countries. The opportunity to reduce the burden 
of these diseases by the recommendation of HZ vaccination have 
been evaluated and suggested also in our Country and some 
Regions have been recently introduced the vaccine in their immu-
nization plan. If the good results, already obtained with HZ vac-
cine in other countries, will be confirmed by these Italian pilot 
experiences, vaccination programs should be made uniform in all 
Country in order to ensure an equitable offer of this important 
preventive tool.
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Summary
Introduction
Herpes zoster is an acute disease, presenting with der-
matologic manifestations and neurological pain, caused 
by the reactivation of the varicella zoster virus (VZV). 
During primary infection, VZV infects skin nervous 
endings and remains latent in the sensory ganglia of the 
spinal dorsal root cord and cranial nerves. Age and im-
mune system depression can favor virus reactivation and 
leads to the peculiar vesicular rash with unilateral and 
dermatomeric localization, known as HZ [1].
The most common complication of HZ is constituted by 
the PHN, a painful syndrome which interests the course 
of the nerve up to cutaneous dermatome corresponding 
to the viral site of infection and reactivation [2-4].
PHN commonly occurs with one or more accesses or 
with paroxysmal pain, burning, allodynia and hyperal-
gesia and current trends define PHN as a chronic neuro-
pathic resilient pain HZ-related that persists or develops 
after at least 90 days after wound healing skin and can 
continue for months or years  [5]. As demonstrated in 
several epidemiological studies, incidence and severity 
of PHN increase with age; furthermore acute pain and 
rash severity were recognized as important risk factors 
for PHN [6-9].
Therapeutic treatments currently available for HZ and 
PHN are not able to ensure a satisfactory management 
of the diseases [5]. This therapeutic gap, together with 
the relevant burden of the diseases, leave unmet medical 
needs that could be satisfied by vaccination programs.
Epidemiology
Incidence of HZ and PHN. Incidence of HZ is compara-
ble all over the world and is closely related with the pop-
ulation age. A recent systematic review, summarizing 
incidence rates of HZ reported in 49 studies performed 
in North America, Europe and Asia, showed that, in 
these three continents, overall HZ incidence rate ranged 
between 3 and 5 cases per 1,000 person/years  [10]. In 
these countries the occurrence of HZ is age-dependent 
and the incidence by age-group shows a similar pattern, 
with rates of 6-8 cases per 1,000 person/year in the sixth 
decade and 8-12 per 1,000 person/year in the eighth dec-
ade [10].
Similarly, the incidence rate of HZ in Europe is esti-
mated with a frequency of 2-3/1,000 person/year in the 
adults aged between 20 and 50 years, 5/1,000 in the sixth 
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decade, 6-7/1,000 from the seventh to the eighth one, 
and increases up to > 1/100 in 90-year-old people [11].
An Italian study, dealing with the immune-competent 
adult population older than 50 years, with an observation 
period of two years (from 2003 to 2005), reported an 
incidence rate of 6.3 per 1,000 person/year, estimating 
that, in a population of approximately 24.2 million peo-
ple aged over 50, at least 153,000 new cases of HZ oc-
cur yearly [12]. This Italian research further confirmed 
that HZ incidence increases with age, therefore older pa-
tients have a greater risk of developing HZ [12].
Furthermore these studies clearly demonstrated that in-
cidence of PHN rises with age. In the afore-mentioned 
systematic review, the risk of developing PHN is esti-
mated between 5% to more than 30% in the adults and 
in patients with HZ who are 50 or older, the risk of PHN 
increased to 25-50% [10]. In Europe, adult patients with 
HZ developed PHN lasting at least 1 month in the 6.5-
38% of cases and PHN lasting at least 3 months in the 
2.6 to 27% of cases;  [13] in Italy it was observed that 
at least 8% of the adult population with HZ presented a 
PHN lasting at least 1 month and the 6.2% experienced 
a PHN lasting at least 3 months. [12] Moreover it was 
shown that the most important risk factors for the de-
velopment of PHN are determined by increasing age, 
female gender and decline of the immune system. [12]
Hospitalization rates for HZ and PHN in adult patients. 
The rates of HZ-related hospitalization, in the 49 coun-
tries included in the global systematic review, ranged 
widely from 2 to 25 per 100,000 person/years in studies 
examining all age groups. Hospitalization with a prima-
ry diagnosis of HZ were about 29-42% of the total HZ-
related hospitalizations and these rates increase steeply 
in adults aged 50 or older [10].
In particular, in the US, HZ-associated hospitalization 
rates (confirmed with medical records) ranged from 
10 per 100,000 in adults aged 60-69 to 65 per 100,000 
in adults aged ≥  80. Similarly, the rate of hospitaliza-
tion with primary diagnosis of HZ ranged from 13 per 
100,000 in adults aged 60-64 to 96 per 100,000 in adults 
aged ≥ 80 in Australia [10]. In Germany, the rates ranged 
from 31 per 100,000 in adults aged 60-64 to 100 per 
100,000 in adults aged ≥ 80 [10].
Gialloreti et  al. analyzed the Italian hospital discharge 
records related to primary diagnosis of HZ disease and 
reported an annual hospitalization rate equal to 10.34 
per 100,000 person/years within immunocompetent pa-
tients older than 50 years. This figure raised to 20.31 per 
100,000 when both the primary and secondary diagnosis 
are considered [12].
Costs related with HZ e PHN. In Italy, the annual costs 
related to the HZ and PHN disease accounted to 41.2 
million euros, of which 28.2 million related to direct 
costs (21.5 million for treatment of acute HZ) and 13 
million associated to indirect costs (12.2 in lost produc-
tivity related to acute episode of HZ) [12]. These figures 
corresponded to a direct cost of 166 € for each patient 
with a HZ episode and 560  € in patients with a PHN 
episode, furthermore the indirect costs were estimated as 
€ 556 in patients with a HZ episode and € 795 in patients 
with PHN [12].
In the hospitalized patients the costs, evaluated for a 
single episode, were approximately € 2,592 ± 1,313 for 
acute HZ and € 5,400 ± 2,641 for PHN [12]. Similarly, 
in another study performed in the Piedmont, one of the 
largest Italian region, the costs related to hospitaliza-
tion for a single case of HZ were estimated to amount to 
€ 4,082.59 [14].
Herpes Zoster vaccine
Efficacy. Since 2006 a live, attenuated varicella zoster 
virus vaccine, that contains VZV Oka strain [Zostavax, 
Merck & Co., Inc.], was licensed for the prevention of 
HZ and PHN in adults aged ≥ 60 years and in 2008 the 
Advisory Committee on Immunization Practices (ACIP) 
recommended its use for the prevention of HZ and its 
complications in individuals aged ≥ 60 [15]. Since 2011, 
the vaccine was authorized also for administration in the 
adults between 50 and 59 by Food and Drug Administra-
tion (FDA) [16].
Short-term efficacy of zoster vaccine in adults aged ≥ 50 
have been demonstrated in two pivotal clinical trials, 
including 38,546 subjects aged more than 60 years and 
22,439 subjects aged 50-59 years, with respect to three 
major outcomes: burden of illness determined by HZ, 
incidence of HZ and incidence of PHN [17, 18].
Figure 1 summarized data about HZ vaccine efficacy 
among adults aged 50 through 59 and ≥ 60 years. Fur-
thermore, both clinical trials and post-marketing studies 
demonstrated the optimal safety and tolerability profile 
of this vaccine [19].
Duration of protection. Duration of protection in adults 
aged ≥ 60 has been studied in two consecutive researches. 
A persistent vaccine efficacy for HZ and PHN has been 
indicated in a short-term persistence substudy (STPS), 
performed within 14,000 subjects. In particular analysis 
of vaccine efficacy in each year after vaccination for the 
HZ burden of illness, the incidence of HZ and the in-
cidence of PHN showed a decrease in vaccine efficacy 
after one year since administration of HZ vaccine, with 
a further decline thereafter. However, vaccine efficacy 
remained statistically significant for the incidence of HZ 
and the HZ burden of illness till five year after HZ vac-
cine administration [20].
Subsequently, a subgroup of 6,000 subjects were en-
rolled in a long-persistence study to evaluated the vac-
cine efficacy up to 11 years after vaccine administration. 
The results, estimated by a model, revealed that vaccine 
efficacy decreased over time in the study population 
compared to modelled control estimates: statistically 
significant vaccine efficacy for HZ Burden of Illness 
persisted up to 10 years after vaccination, whereas statis-
tically significant vaccine efficacy for incidence of HZ 
persisted up to 8 years after vaccination [21].
A recent study, investigating the effect of chronological 
age on the level of protection provided by HZ vaccine 
over time with respect to HZ incidence, demonstrated 
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that much of the reduction in vaccine efficacy over time 
since vaccination can be explained by increasing age, 
responsible for decline of immune response [22].
Effectiveness. After the licensure, the on-field effective-
ness of HZ vaccine was confirmed by two large studies. 
A retrospective cohort study, performed among 75,761 
vaccinated subjects cohort matched to 227,283 unvac-
cinated subjects, demonstrated that vaccination was as-
sociated with a reduced risk of HZ (hazard ratio = 0.45; 
95% CI, 0.42-0.48); this reduction occurred in all age 
strata and among individuals with chronic diseases [23].
A larger cohort study, performed among more than 
700,000 subjects aged > 65 in the period lasting from 
2007 to 2009, confirmed these results, demonstrating a 
vaccine effectiveness, adjusted for age, gender, race, im-
munosuppression, low income, and comorbidity, of 0.48 
(95% CI 0.39-0.56) [24]. This means that an overall vac-
cine effectiveness (VE) of 48% was demonstrated where 
VE was calculated as (1 – the adjusted hazard ratio).
Cost-effectiveness. A recent systematic review identified 
and analyzed 15 cost-effectiveness studies of vaccina-
tion against HZ and PHN performed in North America 
and Europe [25]. Most studies conducted in Europe and 
Canada concluded that HZ vaccine is likely to be cost-
effective and generally supported the economic value of 
this vaccination. Divergences in results among studies 
were largely attributable by authors to differing assump-
tions regarding duration of vaccine protection and a loss 
in quality of life associated with HZ and to a larger ex-
tent, PHN. Moreover, vaccine efficacy against PHN, age 
at vaccination, and vaccine cost strongly influenced the 
results [25].
A pharmaco-economic evaluation performed in Italy 
confirmed that vaccination program against HZ and 
PHN within subjects aged 60-79 years is cost-effective 
from both societal and third-payer standpoints in the 
Italian scenario [19].
Conclusions
HZ and its main complication, PHN, represent an impor-
tant public health issue because of their relevant burden 
within older adult population and the actual suboptimal 
therapeutic management of the diseases.
The licensure since 2006 of a live attenuated HZ vaccine 
in adults aged more than 60 years, extended since 2011 
in adults aged 50-59 years, had stimulated the interest by 
the public health to evaluate the introduction of HZ vac-
cination in these categories in order to reduce the health-
care and economic burden associated with HZ.
The vaccine is actually recommended in USA and Can-
ada in patients ≥ 60 years since 2006 and 2010, respec-
tively. In Europe, vaccination is recommended in sev-
eral countries (i.e. Germany, United Kingdom, Sweden, 
Austria, France) according to age-based strategies [19].
In Italy, available epidemiological and economic data 
about HZ and its complications are superimposable with 
Fig. 1. efficacy of herpes Zoster vaccine registered in two phase III clinical trials [17, 18].
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similar data collected in North America and Europe. 
For these reasons, the opportunity to reduce the burden 
of these diseases by the recommendation of HZ vacci-
nation have been evaluated and suggested also in our 
Country [19].
During 2014, some Italian regions, such as Liguria and 
Puglia, established to introduce HZ vaccination in the 
regional immunization plan by the active and free offer 
of the vaccine to specific age-group.
The administration of HZ vaccine within public health 
strategy in these Regions offers the opportunity to assess 
on-field its safety and tolerability profile and, important-
ly, to evaluate the impact of vaccination on healthcare 
services.
If the good results, already obtained with HZ vaccine in 
other countries, will be confirmed by these Italian pilot 
experiences, vaccination programs should be made uni-
form in all Country in order to ensure an equitable offer 
of this important preventive tool.
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